Abstract | BACKGROUND AND PURPOSE: METHODS: A post hoc subgroup analysis of the already reported Cilostazol Stroke Prevention Study, which was a placebo-controlled double-blind trial, has been carried out to clarify the influence of various complications on recurrence in the placebo group and the effects of cilostazol in 1,095 patients with noncardioembolic ischemic cerebrovascular disease. Treatment continued for an average of 1.8 +/- 1.3 years (maximum 4.8 years). RESULTS: The recurrence rate of the diabetic stroke patients was significantly higher compared with the nondiabetics in the placebo group (9.4 vs. 4.7%/year, p = 0.01). Furthermore, our study showed that the relative risk reduction (RRR) for recurrence of infarction was 41.7% with cilostazol. This treatment provided a significant benefit in patients with lacunar infarction (RRR 43.4%, p = 0.04), with diabetes (RRR 64.4%, p = 0.008), or with hypertension (RRR 58.0%, p = 0.003). CONCLUSIONS:
|
Authors | Yukito Shinohara, Fumio Gotoh, Hideo Tohgi, Shunsaku Hirai, Akiro Terashi, Yasuo Fukuuchi, Eiichi Otomo, Eiichi Itoh, Tamotsu Matsuda, Tohru Sawada, Takenori Yamaguchi, Katsuya Nishimaru, Yasuo Ohashi |
Journal | Cerebrovascular diseases (Basel, Switzerland)
(Cerebrovasc Dis)
Vol. 26
Issue 1
Pg. 63-70
( 2008)
ISSN: 1421-9786 [Electronic] Switzerland |
PMID | 18511873
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | (c) 2008 S. Karger AG, Basel |
Chemical References |
- Platelet Aggregation Inhibitors
- Tetrazoles
- Cilostazol
|
Topics |
- Aged
- Brain Ischemia
(complications, prevention & control)
- Cerebral Infarction
(etiology, prevention & control)
- Cilostazol
- Diabetes Complications
(drug therapy)
- Double-Blind Method
- Female
- Humans
- Hypertension
(complications, drug therapy)
- Japan
- Male
- Middle Aged
- Platelet Aggregation Inhibitors
(therapeutic use)
- Risk Assessment
- Risk Factors
- Secondary Prevention
- Tetrazoles
(therapeutic use)
- Time Factors
- Treatment Outcome
|